company background image
METR

Metropolis Healthcare NSEI:METROPOLIS Stock Report

Last Price

₹1.44k

Market Cap

₹73.5b

7D

-0.3%

1Y

-50.2%

Updated

02 Jul, 2022

Data

Company Financials +
METROPOLIS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance3/6
Financial Health5/6
Dividends3/6

METROPOLIS Stock Overview

Metropolis Healthcare Limited provides diagnostic services in India.

Metropolis Healthcare Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Metropolis Healthcare
Historical stock prices
Current Share Price₹1,436.35
52 Week High₹3,579.90
52 Week Low₹1,378.05
Beta0.56
1 Month Change-8.86%
3 Month Change-31.31%
1 Year Change-50.20%
3 Year Change46.96%
5 Year Changen/a
Change since IPO49.64%

Recent News & Updates

Jun 07
Metropolis Healthcare (NSE:METROPOLIS) Has A Rock Solid Balance Sheet

Metropolis Healthcare (NSE:METROPOLIS) Has A Rock Solid Balance Sheet

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Shareholder Returns

METROPOLISIN HealthcareIN Market
7D-0.3%-0.2%0.6%
1Y-50.2%-4.0%-0.2%

Return vs Industry: METROPOLIS underperformed the Indian Healthcare industry which returned -4% over the past year.

Return vs Market: METROPOLIS underperformed the Indian Market which returned -0.2% over the past year.

Price Volatility

Is METROPOLIS's price volatile compared to industry and market?
METROPOLIS volatility
METROPOLIS Average Weekly Movement6.4%
Healthcare Industry Average Movement5.9%
Market Average Movement6.8%
10% most volatile stocks in IN Market9.8%
10% least volatile stocks in IN Market4.4%

Stable Share Price: METROPOLIS is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: METROPOLIS's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19803,711Vijender Singhhttps://www.metropolisindia.com

Metropolis Healthcare Limited provides diagnostic services in India. The company offers clinical laboratory testing, and profiles and support services to patients, smaller labs, nursing homes, and hospitals. It provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, and youth and corporates.

Metropolis Healthcare Fundamentals Summary

How do Metropolis Healthcare's earnings and revenue compare to its market cap?
METROPOLIS fundamental statistics
Market Cap₹73.50b
Earnings (TTM)₹2.14b
Revenue (TTM)₹12.28b

34.3x

P/E Ratio

6.0x

P/S Ratio

Is METROPOLIS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
METROPOLIS income statement (TTM)
Revenue₹12.28b
Cost of Revenue₹2.76b
Gross Profit₹9.52b
Other Expenses₹7.38b
Earnings₹2.14b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)41.85
Gross Margin77.53%
Net Profit Margin17.44%
Debt/Equity Ratio29.1%

How did METROPOLIS perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

19%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is METROPOLIS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for METROPOLIS?

Other financial metrics that can be useful for relative valuation.

METROPOLIS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6.1x
Enterprise Value/EBITDA22x
PEG Ratio3.4x

Price to Earnings Ratio vs Peers

How does METROPOLIS's PE Ratio compare to its peers?

METROPOLIS PE Ratio vs Peers
The above table shows the PE ratio for METROPOLIS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average32.3x
539871 Thyrocare Technologies
18.5x-3.3%₹32.6b
VIJAYA Vijaya Diagnostic Centre
32.6x10.1%₹35.8b
539524 Dr. Lal PathLabs
53.6x11.7%₹184.7b
543328 Krsnaa Diagnostics
24.3x24.5%₹16.6b
METROPOLIS Metropolis Healthcare
34.3x10.2%₹73.5b

Price-To-Earnings vs Peers: METROPOLIS is expensive based on its Price-To-Earnings Ratio (34.3x) compared to the peer average (32.3x).


Price to Earnings Ratio vs Industry

How does METROPOLIS's PE Ratio compare vs other companies in the IN Healthcare Industry?

Price-To-Earnings vs Industry: METROPOLIS is expensive based on its Price-To-Earnings Ratio (34.3x) compared to the Indian Healthcare industry average (28.9x)


Price to Earnings Ratio vs Fair Ratio

What is METROPOLIS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

METROPOLIS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio34.3x
Fair PE Ratio36.1x

Price-To-Earnings vs Fair Ratio: METROPOLIS is good value based on its Price-To-Earnings Ratio (34.3x) compared to the estimated Fair Price-To-Earnings Ratio (36.1x).


Share Price vs Fair Value

What is the Fair Price of METROPOLIS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: METROPOLIS (₹1436.35) is trading above our estimate of fair value (₹906.2)

Significantly Below Fair Value: METROPOLIS is trading above our estimate of fair value.


Price to Earnings Growth Ratio

PEG Ratio: METROPOLIS is poor value based on its PEG Ratio (3.4x)


Discover undervalued companies

Future Growth

How is Metropolis Healthcare forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


10.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: METROPOLIS's forecast earnings growth (10.2% per year) is above the savings rate (6.8%).

Earnings vs Market: METROPOLIS's earnings (10.2% per year) are forecast to grow slower than the Indian market (17.4% per year).

High Growth Earnings: METROPOLIS's earnings are forecast to grow, but not significantly.

Revenue vs Market: METROPOLIS's revenue (10.2% per year) is forecast to grow slower than the Indian market (11.5% per year).

High Growth Revenue: METROPOLIS's revenue (10.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: METROPOLIS's Return on Equity is forecast to be high in 3 years time (22%)


Discover growth companies

Past Performance

How has Metropolis Healthcare performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


19.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: METROPOLIS has high quality earnings.

Growing Profit Margin: METROPOLIS's current net profit margins (17.4%) are lower than last year (18.3%).


Past Earnings Growth Analysis

Earnings Trend: METROPOLIS's earnings have grown by 19.5% per year over the past 5 years.

Accelerating Growth: METROPOLIS's earnings growth over the past year (17%) is below its 5-year average (19.5% per year).

Earnings vs Industry: METROPOLIS earnings growth over the past year (17%) underperformed the Healthcare industry 78.3%.


Return on Equity

High ROE: METROPOLIS's Return on Equity (24.2%) is considered high.


Discover strong past performing companies

Financial Health

How is Metropolis Healthcare's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: METROPOLIS's short term assets (₹3.9B) exceed its short term liabilities (₹3.0B).

Long Term Liabilities: METROPOLIS's short term assets (₹3.9B) exceed its long term liabilities (₹3.4B).


Debt to Equity History and Analysis

Debt Level: METROPOLIS's net debt to equity ratio (8.8%) is considered satisfactory.

Reducing Debt: METROPOLIS's debt to equity ratio has increased from 0.3% to 29.1% over the past 5 years.

Debt Coverage: METROPOLIS's debt is well covered by operating cash flow (98%).

Interest Coverage: METROPOLIS's interest payments on its debt are well covered by EBIT (14.2x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Metropolis Healthcare current dividend yield, its reliability and sustainability?

Dividend Score

3/6

Dividend Score 3/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


0.56%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: METROPOLIS's dividend (0.56%) is higher than the bottom 25% of dividend payers in the Indian market (0.42%).

High Dividend: METROPOLIS's dividend (0.56%) is low compared to the top 25% of dividend payers in the Indian market (1.86%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, METROPOLIS has been paying a dividend for less than 10 years.

Growing Dividend: METROPOLIS has only been paying a dividend for 2 years, and since then payments have not increased.


Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (19.1%), METROPOLIS's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (18.4%), METROPOLIS's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Vijender Singh

6.33yrs

Tenure

₹317,442,000

Compensation

Mr. Vijender Singh has been Chief Executive Officer of Metropolis Healthcare Limited since March 16, 2016. Mr. Singh joined Metropolis Healthcare Ltd in 2016 and is responsible for driving the overall grow...


CEO Compensation Analysis

Compensation vs Market: Vijender's total compensation ($USD4.02M) is above average for companies of similar size in the Indian market ($USD334.04K).

Compensation vs Earnings: Vijender's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: METROPOLIS's management team is considered experienced (2 years average tenure).


Board Members

Experienced Board: METROPOLIS's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Metropolis Healthcare Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Metropolis Healthcare Limited
  • Ticker: METROPOLIS
  • Exchange: NSEI
  • Founded: 1980
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: ₹73.505b
  • Shares outstanding: 51.17m
  • Website: https://www.metropolisindia.com

Number of Employees


Location

  • Metropolis Healthcare Limited
  • 250-D, Udyog Bhavan
  • Hind Cycle Marg
  • Mumbai
  • Maharashtra
  • 400030
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/02 00:00
End of Day Share Price2022/07/01 00:00
Earnings2022/03/31
Annual Earnings2022/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.